Although non-selective TNF inhibitors have demonstrated some efficacy in single cases of human SCI [61] and in preclinical SCI models (reviewed in [8]), the risk of adverse effects [33], including CNS demyelinating disease [34,62], exceeds the potential benefit of their use in neurological patients. This evidence concerns the gene TNF and demyelinating disease of central nervous system.